NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Lyell Immunopharma, Inc. LYEL
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$36,000
▼ 41.0% vs FY2024
EPS · FY25
$-16.06
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-87.0%
Net margin · FY25
-762355.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 36,000.00
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 762356 cents on every revenue dollar this year.
Per share
USD -16.06
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-87.0%
Return on equity, FY2025
ROE
Operating margin-748344.4%
Net margin-762355.6%
Return on assets-66.1%
Each USD of equity lost 87 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−65.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−92.5%
−65.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 340.1M
total assets, end of FY2025
Total assetsUSD 340.1M
EquityUSD 248.2M
CashUSD 60.2M
Current ratio5.28×
Equity funds 73% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.0
0.0
0.1
0.0
0.0
0.0
Operating income $B
−0.3
−0.4
−0.2
−0.2
−0.2
−0.2
−0.1
EBITDA $B
−0.3
−0.3
−0.2
−0.2
−0.2
−0.2
−0.1
Income tax $B
0.0
·
·
·
·
·
·
Net income $B
−0.3
−0.3
−0.2
−0.2
−0.3
−0.2
−0.1
EPS, diluted $
−16.06
−26.23
−18.70
−0.74
−1.84
−15.69
−24.04
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−87.0
−66.1
−31.5
−20.8
−78.5
·
·
Shares out B
0.02
0.01
0.25
0.25
0.24
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
19 of 19
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed